VolitionRX Ltd (VNRX)

In the past six months, VolitionRx secured $2.0 million in funding and announced breakthrough clinical data for its Nu.Q® Vet Feline assay, leading to a positive market reaction. Volition issued its Business Review 2025, outlining commercial, clinical, and intellectual property milestones, including the first clinical order for Nu.Q® Cancer assays for lung cancer and the inclusion of Nu.Q® NETs assay in a French sepsis evaluation program. Volition announced a technological advancement with its Capture-Seq™ method, achieving 180-fold enrichment for liquid biopsy. Two abstracts were presented at the North America Conference on Lung Cancer. VolitionRx Limited announced the inclusion of its Nu.Q® NETs Assay as an innovative biomarker in France's real-world evaluation of early detection of sepsis. VolitionRx Limited announced the first sale of the Nu.Q® Cancer Assays for clinical certification. VolitionRx reported Q3 2025 revenue of $0.6M but missed EPS expectations. VolitionRx Limited completed a Follow-on Equity Offering of $6.006 million. VolitionRx's Nu.Q NETs product generated the company's first recurring revenue stream. Volition announced a Lateral Flow Test for Point-of-Care Quantification of Nucleosomes. The share price as of January 9, 2026, was $0.33, representing a decline of 48.93% from $0.65 on January 10, 2025, but VNRX shares have increased by 24.4% since the start of 2026, trading at $0.3180.

Information regarding the specific demand seasonality for VolitionRX Ltd.'s products and services is not readily available.

VolitionRX Ltd. is a multi-national epigenetics company focused on improving outcomes for humans and animals with life-altering diseases through early detection and disease monitoring, operating in the Healthcare sector, specifically in Biotechnology & Medical Research, Diagnostics, Health Technology, and Medical Specialties. The company's core business is its Nucleosomics® technology, which identifies epigenetic and structural changes in nucleosomes in blood samples to detect disease-specific biomarkers. Key products include Nu.Q® Vet, a cancer screening test for animals; Nu.Q® NETs, for detecting and monitoring diseases associated with NETosis; Nu.Q® Discover, a solution for profiling nucleosomes; Nu.Q® Cancer, aimed at predicting and monitoring cancer treatment response; and Capture-PCR™ and Capture-Seq™ technologies for isolating circulating tumor-derived DNA.

VolitionRX Ltd. is a multi-national company with a global presence, with research and development primarily in Belgium. It maintains an innovation laboratory and office in the United States, and additional offices in London and Singapore. The company develops and commercializes its blood tests in the United States, Europe, and Asia. The Nu.Q® Vet Cancer Test is available in over 20 countries, and the Nu.Q® NETs test has been adopted by hospital networks across five European countries.

VolitionRX Ltd.'s reputation has been positively influenced by scientific and commercial advancements, including breakthrough clinical data for its Nu.Q® Vet Feline assay, which is expected to lead to the first blood-based liquid biopsy test for feline cancer. The Nu.Q® NETs product has generated its first revenue and is being implemented in hospital networks across Europe, with its inclusion in a government-backed sepsis evaluation program in France enhancing the company's standing. The company's focus on commercializing its Nu.Q® platform and signing licensing agreements contributes to a positive brand image, and scientific progress, including the Capture-Seq™ method, bolsters its reputation as an innovator in epigenetics.

VolitionRX Ltd. has a mixed ownership structure comprising institutional, insider, and retail investors. Approximately 20.23% of the company's stock is owned by Institutional Investors, 10.40% is owned by Insiders, and 69.36% is owned by Public Companies and Individual Investors. Major institutional owners include Lagoda Investment Management, L.P., Armistice Capital, Llc, Vanguard Group Inc., Geode Capital Management, Llc, BlackRock, Inc., Citadel Advisors Llc, State Street Corp, and Silverberg Bernstein Capital Management LLC. The largest individual shareholder is Eight Corp Ltd, owning 12.01 million shares, representing 9.78% of the company. Cameron John Reynolds, the CEO, directly owns 1.6% of the company's shares.